Puzo Michael J Buys 2,205 Shares of Danaher Corporation (NYSE:DHR)

Puzo Michael J boosted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 4.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,507 shares of the conglomerate's stock after purchasing an additional 2,205 shares during the period. Danaher comprises 2.8% of Puzo Michael J's holdings, making the stock its 17th largest position. Puzo Michael J's holdings in Danaher were worth $9,739,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Broderick Brian C lifted its position in shares of Danaher by 1.5% during the 1st quarter. Broderick Brian C now owns 66,296 shares of the conglomerate's stock valued at $13,591,000 after buying an additional 1,007 shares during the last quarter. Shepherd Financial Partners LLC lifted its position in shares of Danaher by 1.6% during the 1st quarter. Shepherd Financial Partners LLC now owns 8,993 shares of the conglomerate's stock valued at $1,844,000 after buying an additional 143 shares during the last quarter. Hemenway Trust Co LLC lifted its position in shares of Danaher by 4.8% during the 1st quarter. Hemenway Trust Co LLC now owns 168,909 shares of the conglomerate's stock valued at $34,626,000 after buying an additional 7,726 shares during the last quarter. Birch Hill Investment Advisors LLC lifted its position in shares of Danaher by 16.8% during the 1st quarter. Birch Hill Investment Advisors LLC now owns 3,402 shares of the conglomerate's stock valued at $697,000 after buying an additional 490 shares during the last quarter. Finally, Global Trust Asset Management LLC lifted its position in shares of Danaher by 42.9% during the 1st quarter. Global Trust Asset Management LLC now owns 1,242 shares of the conglomerate's stock valued at $255,000 after buying an additional 373 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insiders Place Their Bets

In other news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Trading Down 0.7%

DHR traded down $1.39 on Thursday, hitting $194.36. 3,236,239 shares of the company were exchanged, compared to its average volume of 3,488,121. The firm has a fifty day simple moving average of $193.74 and a two-hundred day simple moving average of $210.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70. The stock has a market capitalization of $139.10 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 2.73 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.66%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Analysts Set New Price Targets

DHR has been the topic of a number of recent research reports. TD Cowen upped their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Bank of America dropped their price objective on Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. HSBC dropped their price objective on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Finally, Evercore ISI dropped their price objective on Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a report on Tuesday, April 22nd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.